VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 02, 2008) - Tekmira Pharmaceuticals Corporation (“Tekmira”) (TSX: TKM) and Protiva Biotherapeutics Inc. (“Protiva”) announced today that they have completed the business combination between the two companies. The combined company, which will retain the name Tekmira, will be a global leader in the field of RNA interference (“RNAi”) therapeutics.
